All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATR-01
Therapeutic Area: Dermatology Product Name: ATR-01
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 15, 2020
Details:
The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and consumer programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tapinarof
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Derm-Biome's topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. The drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-003
Therapeutic Area: Dermatology Product Name: HT-003
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KB301
Therapeutic Area: Dermatology Product Name: KB301
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
KB301 is designed to restore collagen homeostasis locally via directed COL3A1 expression, thereby reconstructing an optimal physiologic environment in the skin to treat wrinkles and other superficial skin defects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibiotic,Zinc chelator
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
Study to determine the safety, tolerability, pharmacokinetics and efficacy of twice daily application of topical BioLexa in healthy subjects and patients with mild to moderate atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VNLG 152
Therapeutic Area: Dermatology Product Name: VNLG 152
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Isoprene Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2020
Details:
Isoprene Pharmaceuticals will acquire rights to Hoth's VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,000.0 million Upfront Cash: $150.0 million
Deal Type: Partnership July 09, 2020
Details:
Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter. Sanofi will lead all clinical development activities for the second program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATI-1777
Therapeutic Area: Dermatology Product Name: ATI-1777
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Aclaris plans to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): WEG232
Therapeutic Area: Dermatology Product Name: WEG232
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: George Washington University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Details:
Hoth Therapeutics has expanded its research agreement with the George Washington University to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VNLG 152
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
Management provides pipeline update for assets including BioLexa Platform (Dermatological), VNLG-152 (Dermatological), WEG-232 (Dermatological), VaxCelerate (COVID-19), Novel Peptide Therapeutic (COVID-19), AEA-loaded Z-pods™ (Lupus), Exon Skipping Approach (Allergic Disease).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
